Eli Lilly and Company

Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007

    Indianapolis (ots/PRNewswire) -

    - 37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 Targeted Agent Studies

    Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1-5, 2007. The company will present important data on GEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexed for injection), and enzastaurin, an investigational, oral, targeted therapy. There will also be numerous studies that continue to use GEMZAR and ALIMTA as chemotherapeutic foundations in innovative combinations with new targeted therapies.

    "This is an exciting time in cancer research as we are moving away from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "Lilly's commitment to finding the right drug, at the right dose, for the right patient at the right time will be demonstrated at ASCO this year."

@@start.t1@@      Key Lilly Abstracts for ASCO 2007:
      -- ALIMTA(R) (pemetrexed for injection)
            -- Phase III Study of ALIMTA in First-line NSCLC
                  -- Abstract # 7517: June 2, 2007; 3:00 p.m.
                  -- Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the
                        treatment of stage IIIB/IV NSCLC
            -- Large Meta-analysis of Diverse Patients with NSCLC
                  -- Publication: 2007 ASCO Meeting Program
                  -- Effect of race on the safety and efficacy of pemetrexed
                        therapy in locally advanced and metastatic non-small cell lung
                        cancer (NSCLC)
            -- Phase II Evaluation of ALIMTA Using Accelerated Vitamin
                 Supplementation in Small Cell Lung Cancer
                  -- Abstract # 7726: June 3, 2007: 8:00 a.m.
                  -- The impact of shortened vitamin supplementation lead-in time
                        before pemetrexed in patients with relapsed small cell lung
                        cancer (SCLC)
            -- Early-phase Trial of ALIMTA +/- Steroids in Head & Neck Cancer
                  -- Abstract # 6055: June 4, 2007: 1:00 p.m.
                  -- A phase I dose escalation study of pemetrexed in patients with
                        advanced head and neck squamous cell cancer
      -- GEMZAR(R) (gemcitabine HCl for injection)
            -- Phase III Study of GEMZAR Combination in Neoadjuvant
                 (Pre-Surgical) Breast Cancer
                  -- Abstract # 595: June 2, 2007; 2:00 p.m.
                  -- Neoadjuvant chemotherapy with a dose-dense sequential
                        combination of epirubicin and cyclophosphamide followed by
                        paclitaxel and gemcitabine +/- trastuzumab in stage II and III
                        breast cancer
      -- Enzastaurin
            -- Phase II Data of Targeted, Oral Agent enzastaurin in Second- &
                 Third-line NSCLC
                  -- Abstract # 7543: June 2, 2007; 8:00 a.m.
                  -- A phase II study of enzastaurin as second- or third-line
                        treatment of non-small cell lung cancer (NSCLC)@@end@@

    For more information on Lilly Oncology agents, including full prescribing information, please see the attached fact sheet, or, if you are receiving this electronically, you can view full prescribing information on www.lillyoncology.com.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

ots Originaltext: Eli Lilly and Company
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Gregory L. Clarke, +1-317-276-5222, or Mobile, +1-317-554-7119, or
Christine Van Marter, +1-317-651-1473, or Mobile, +1-317-554-7923,
both of Eli Lilly and Company; Photo:  NewsCom:  
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, PRN Photo Desk,
photodesk@prnewswire.com



Weitere Meldungen: Eli Lilly and Company

Das könnte Sie auch interessieren: